X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2802) 2802
Book / eBook (33) 33
Web Resource (12) 12
Book Chapter (7) 7
Journal / eJournal (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Magazine Article (1) 1
Publication (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1849) 1849
animals (1714) 1714
immunotoxins - pharmacology (1229) 1229
mice (936) 936
index medicus (656) 656
immunotoxins (608) 608
oncology (605) 605
immunotoxin (578) 578
female (553) 553
pharmacology & pharmacy (497) 497
male (487) 487
immunotoxins - therapeutic use (470) 470
rats (414) 414
ribosome inactivating proteins, type 1 (391) 391
cancer (355) 355
antibodies, monoclonal - pharmacology (353) 353
cell line, tumor (341) 341
immunology (334) 334
tumor cells, cultured (328) 328
n-glycosyl hydrolases (296) 296
immunotoxins - immunology (281) 281
antineoplastic agents - pharmacology (273) 273
biochemistry & molecular biology (269) 269
antibodies, monoclonal - therapeutic use (259) 259
cell survival - drug effects (257) 257
immunotoxins - toxicity (245) 245
recombinant fusion proteins - pharmacology (244) 244
mice, nude (239) 239
expression (238) 238
antibodies, monoclonal - immunology (237) 237
mice, inbred balb c (236) 236
immunotoxins - chemistry (228) 228
immunotherapy (218) 218
cell line (217) 217
immunotoxins - metabolism (216) 216
neurosciences (215) 215
dose-response relationship, drug (205) 205
plant proteins - pharmacology (205) 205
immunotoxins - administration & dosage (203) 203
monoclonal-antibody (202) 202
medicine, research & experimental (197) 197
antibodies, monoclonal (196) 196
therapy (196) 196
proteins (186) 186
toxicology (186) 186
pseudomonas exotoxin (185) 185
monoclonal-antibodies (183) 183
ricin - pharmacology (181) 181
antibodies (178) 178
saporins (176) 176
cells (171) 171
cytotoxicity (169) 169
rats, sprague-dawley (164) 164
exotoxins - pharmacology (161) 161
apoptosis (157) 157
xenograft model antitumor assays (157) 157
molecular sequence data (152) 152
recombinant immunotoxin (152) 152
immunotoxins - genetics (149) 149
immunotoxins - pharmacokinetics (149) 149
antineoplastic agents - therapeutic use (141) 141
antitumor-activity (139) 139
cells, cultured (139) 139
tumor cells, cultured - drug effects (139) 139
t-lymphocytes - immunology (138) 138
apoptosis - drug effects (137) 137
neoplasms - drug therapy (137) 137
in-vitro (133) 133
ricin (127) 127
amino acid sequence (125) 125
antibodies, monoclonal - administration & dosage (124) 124
phase-i (123) 123
ribosome-inactivating proteins (123) 123
tumors (123) 123
monoclonal antibodies (121) 121
recombinant fusion proteins - genetics (119) 119
hematology (118) 118
toxicity (118) 118
flow cytometry (117) 117
research (117) 117
phase-i trial (116) 116
antibody (115) 115
neoplasm transplantation (115) 115
analysis (111) 111
adp ribose transferases (110) 110
cell biology (109) 109
cell division - drug effects (109) 109
leukemia (108) 108
ricin-a-chain (108) 108
toxins (108) 108
virulence factors (107) 107
time factors (106) 106
recombinant proteins - pharmacology (105) 105
saporin (105) 105
diphtheria-toxin (103) 103
protein (102) 102
antibody-toxin conjugates (100) 100
bacterial toxins - pharmacology (98) 98
fusion protein (98) 98
kinetics (98) 98
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2815) 2815
Chinese (60) 60
Russian (15) 15
Japanese (14) 14
French (3) 3
Spanish (2) 2
German (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 11/2015, Volume 75, Issue 17, pp. 1993 - 2016
Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | IMMUNOTOXIN RFB4(DSFV)-PE38 BL22 | PEGYLATED LIPOSOMAL DOXORUBICIN | EPOTHILONE-B ANALOG | DRUG-RESISTANT PHENOTYPE | GEMTUZUMAB OZOGAMICIN | PHASE-I TRIAL | METASTATIC BREAST-CANCER | ERIBULIN MESYLATE E7389 | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ANTI-MESOTHELIN IMMUNOTOXIN | CHRONIC MYELOID-LEUKEMIA | Dioxoles - therapeutic use | Diphtheria Toxin - pharmacology | Recombinant Fusion Proteins - pharmacology | Furans - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Epothilones - pharmacology | Drug Discovery - methods | Antineoplastic Agents - therapeutic use | Biological Products - pharmacology | Epothilones - therapeutic use | Harringtonines - therapeutic use | Furans - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Diphtheria Toxin - therapeutic use | Immunoconjugates - pharmacology | Cytochalasins - pharmacology | Dioxoles - pharmacology | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Ketones - therapeutic use | Cytochalasins - therapeutic use | Biological Products - therapeutic use | Ketones - pharmacology | Tetrahydroisoquinolines - pharmacology | Tetrahydroisoquinolines - therapeutic use | Withanolides - pharmacology | Harringtonines - pharmacology | Interleukin-2 - pharmacology | Withanolides - therapeutic use | Index Medicus
Journal Article
Immunopharmacology and immunotoxicology, ISSN 0892-3973, 1987
Journal
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 1, pp. e0210608 - e0210608
Standard treatment, unfortunately, yields a poor prognosis for patients with primary or metastatic cancers in the central nervous system, indicating a... 
CELLS | APOPTOSIS | ACTIVATION | MELANOMA | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | IMMUNOTOXIN THERAPY | PROTEOGLYCAN | INHIBITOR | PROMOTES | EXPRESSION | Thiophenes - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Furin - pharmacology | Immunotoxins - pharmacology | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Proto-Oncogene Proteins c-bcl-2 - metabolism | Brain Neoplasms - secondary | Isoquinolines - pharmacology | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Time Factors | Nitrophenols - therapeutic use | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Cell Death - drug effects | Benzothiazoles - pharmacology | Endocytosis - drug effects | Chondroitin Sulfate Proteoglycans - metabolism | Thiophenes - pharmacology | Exotoxins - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Brain Neoplasms - drug therapy | Sulfonamides - pharmacology | Piperazines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Immunotoxins - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Models, Biological | Pyrimidines - therapeutic use | Survival Analysis | Cell Line, Tumor | Isoquinolines - therapeutic use | Benzothiazoles - therapeutic use | Care and treatment | Prognosis | Brain tumors | Central nervous system diseases | Research | Antibody-toxin conjugates | Health aspects | Brain | Animal models | Bcl-2 protein | Laboratories | Toxicity | Brain cancer | Xenotransplantation | Lung cancer | Central nervous system | Glioblastoma | Cytotoxicity | Metastasis | Neurosurgery | Kinases | Cancer therapies | Anticancer properties | Metastases | Proteins | Xenografts | Antigens | Proteoglycans | Melanoma | Poly(ADP-ribose) polymerase | Breast cancer | Pharmacology | Tumor cell lines | Patients | Chemical compounds | Immunotoxins | Pathology | Chemotherapy | Pancreatic cancer | Antitumor activity | Sensitivity enhancement | Chondroitin sulfate | Synergistic effect | Apoptosis | Tumors | Index Medicus
Journal Article
Nature biotechnology, ISSN 1546-1696, 2008, Volume 26, Issue 8, pp. 925 - 932
Journal Article
The FEBS Journal, ISSN 1742-464X, 12/2011, Volume 278, Issue 23, pp. 4683 - 4700
Journal Article
Blood, ISSN 1528-0020, 2009, Volume 113, Issue 16, pp. 3792 - 3800
Immunotoxins based on Pseudomonas exotoxin A (PE) are promising anticancer agents that combine a variable fragment (Fv) from an antibody to a tumor-associated... 
Immunoglobulin Variable Region - adverse effects | Virulence Factors - genetics | Exotoxins - pharmacokinetics | Humans | Antibodies, Monoclonal - adverse effects | Bacterial Toxins - pharmacokinetics | Immunotoxins - adverse effects | Immunotoxins - pharmacology | Endosomes - metabolism | Exotoxins - adverse effects | Lysosomes - metabolism | Virulence Factors - pharmacokinetics | ADP Ribose Transferases - pharmacokinetics | Bacterial Toxins - genetics | Female | Sialic Acid Binding Ig-like Lectin 2 | ADP Ribose Transferases - adverse effects | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Clinical Trials as Topic | Exotoxins - pharmacology | Bacterial Toxins - adverse effects | Xenograft Model Antitumor Assays | ADP Ribose Transferases - genetics | Antibodies, Monoclonal - genetics | Immunotoxins - genetics | Animals | Bacterial Toxins - pharmacology | Mice, Nude | ADP Ribose Transferases - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Exotoxins - genetics | Immunoglobulin Variable Region - pharmacology | Immunoglobulin Variable Region - genetics | Immunotoxins - pharmacokinetics | Mice | Mice, Inbred BALB C | Virulence Factors - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mutation | Virulence Factors - pharmacology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Journal of applied toxicology, ISSN 0260-437X, 07/2015, Volume 35, Issue 7, pp. 831 - 841
Previously, we identified 25 classifier genes that were able to assess immunotoxicity using human Jurkat T cells. The present study aimed to validate these... 
Fluidigm | genomic | ToxPi | qRT-PCR | classifier | prediction | immunotoxicity | Jurkat | biomarker | high throughput | qRT‐PCR | High throughput | Biomarker | Immunotoxicity | Prediction | Classifier | Genomic | QRT-PCR | VITAMIN-C | ACTIVATION | POLYCYCLIC AROMATIC-HYDROCARBONS | KINASE | TETRABROMOBISPHENOL-A | RATS | BALB/C MICE | CHLORPYRIFOS | BROMINATED FLAME RETARDANTS | TOXICOLOGY | EXPOSURE | ortho-Aminobenzoates - pharmacology | Humans | Biomarkers, Pharmacological | Neonicotinoids | Immunotoxins - pharmacology | Pyrethrins - pharmacology | Benzopyrenes - toxicity | Sensitivity and Specificity | Nitro Compounds - pharmacology | Imidazoles - toxicity | Benzopyrenes - pharmacology | Chlorohydrins - pharmacology | Azo Compounds - pharmacology | Real-Time Polymerase Chain Reaction | Pyrethrins - toxicity | Reproducibility of Results | Nitro Compounds - toxicity | Imidazoles - pharmacology | Azo Compounds - toxicity | Aldicarb - pharmacology | Genetic Markers - drug effects | Chlorohydrins - toxicity | Aldicarb - toxicity | Chlorpyrifos - toxicity | Chlorpyrifos - pharmacology | In Vitro Techniques | ortho-Aminobenzoates - toxicity | Toxicity Tests | Jurkat Cells - drug effects | T cells | Analysis | Biomarkers | Cellular biology | Toxicity | Genomics | Index Medicus | kinase | brominated flame retardants | exposure | chlorpyrifos | polycyclic aromatic-hydrocarbons | tetrabromobisphenol-a | balb/c mice | vitamin-c | rats | activation
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 381, Issue 2, pp. 323 - 330
Journal Article
Molecular cancer therapeutics, ISSN 1538-8514, 2011, Volume 10, Issue 10, pp. 1829 - 1838
A novel anticancer agent was constructed by fusing a gene encoding the scFV that targets both glycosylated and unglycosylated forms of CD133 to a gene fragment... 
RECOMBINANT IMMUNOTOXIN | STEM-CELLS | IMMUNOGENICITY | ONCOLOGY | IN-VIVO | DIFFERENTIATION | IDENTIFICATION | AC133 | CARCINOMA | LIGAND-DIRECTED TOXIN | CD133 | Antigens, CD - immunology | Virulence Factors - genetics | Recombinant Fusion Proteins - pharmacology | Antigens, CD - biosynthesis | Neoplastic Stem Cells - drug effects | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Exotoxins - pharmacokinetics | Humans | Bacterial Toxins - pharmacokinetics | Peptides - genetics | Immunotoxins - pharmacology | Antigens, CD - genetics | Head and Neck Neoplasms - metabolism | Transfection | Virulence Factors - pharmacokinetics | ADP Ribose Transferases - pharmacokinetics | Bacterial Toxins - genetics | Female | Glycoproteins - genetics | Cell Survival - drug effects | Cell Growth Processes - drug effects | Peptides - immunology | Head and Neck Neoplasms - drug therapy | Exotoxins - pharmacology | AC133 Antigen | Immunoglobulin Fragments - pharmacology | Head and Neck Neoplasms - pathology | Glycoproteins - biosynthesis | Xenograft Model Antitumor Assays | ADP Ribose Transferases - genetics | Glycoproteins - immunology | Immunotoxins - genetics | Animals | Carcinoma, Squamous Cell - drug therapy | Bacterial Toxins - pharmacology | Mice, Nude | ADP Ribose Transferases - pharmacology | Recombinant Fusion Proteins - pharmacokinetics | Exotoxins - genetics | Cell Line, Tumor | Recombinant Fusion Proteins - genetics | Head and Neck Neoplasms - genetics | Immunoglobulin Fragments - genetics | Immunotoxins - pharmacokinetics | Mice | Mice, Inbred BALB C | Virulence Factors - pharmacology | xenograft model | cancer stem cells | head and neck cancer | pseudomonas exotoxin
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 09/2016, Volume 33, Issue 9, pp. 2218 - 2228
To investigate the applicability of fusion biotoxins combining pore-forming toxins (PFTs) and ribosome-inactivating proteins (RIPs) for the anti-cancer... 
cancer | gelonin | melittin | toxin | ribosome inactivating protein | CELLS | MECHANISM